Trials / Recruiting
RecruitingNCT06710990
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
A Multicenter, Open-label, Fixed-sequence Study to Evaluate Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 | SHR-A1811 |
| DRUG | Ritonavir | Ritonavir |
| DRUG | Itraconazole | Itraconazole |
Timeline
- Start date
- 2025-02-17
- Primary completion
- 2025-06-01
- Completion
- 2026-08-01
- First posted
- 2024-12-02
- Last updated
- 2025-03-28
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06710990. Inclusion in this directory is not an endorsement.